Utilization and Clinical Outcome Following 5-Aminosalicylate Therapy for Crohn's Disease in Children

Le résumé fourni par la source

Objectives: Despite little data on efficacy, 5-Aminosalicylates (5-ASA) are commonly used in pediatric Crohn's Disease (CD).Our aim was to assess prevalence of 5-ASA utilization in children newly diagnosed with CD, as well as clinical outcomes among these patients.Study design: Data were obtained from a large observational inception cohort from 2002-2014.First, we analyzed initial treatments received immediately following diagnosis.Then, clinical outcome and disease activity were measured using the "Physician Global Assessment" (PGA) scale.The primary outcome was a PGA of "inactive", without corticosteroids (CS), immunomodulators, biologics or surgery one year following diagnosis in patients receiving 5-ASA ± CS only as initial therapy following diagnosis.Results: 440/1297 subjects with CD (34%) received 5-ASA ± CS only as initial therapy, and were the focus of this study.No baseline differences were observed between the 5-ASA + CS (n=263) vs. 5-ASA -CS (n=177) treatment groups for age, gender, disease distribution or disease behavior.Baseline moderate/severe PGA was more common in the 5-ASA + CS group compared with the 5-ASA alone group (70% vs. 38%, p<0.001).The primary outcome was achieved by 34% of those treated with 5-ASA alone vs. 18% of those treated with 5-ASA + CS (p<0.001).In multivariate models, achieving the primary outcome was significantly associated with initially mild disease severity and no initial CS use. Conclusion:The prevalence of 5-ASA utilization for pediatric CD is high despite a low likelihood of achieving clinical remission on 5-ASA therapy, although somewhat more favorable for select children with mild disease who do not receive CS at diagnosis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.